ID   TF-1
AC   CVCL_0559
SY   TF1; MFD-1
DR   BTO; BTO:0004760
DR   CLO; CLO_0009325
DR   CLO; CLO_0009326
DR   MCCL; MCC:0000460
DR   CLDB; cl4503
DR   CLDB; cl7163
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-2003
DR   BCRC; 60323
DR   BCRJ; 0233
DR   BioGRID_ORCS_Cell_line; 219
DR   BioSample; SAMN03470850
DR   BioSample; SAMN10988443
DR   cancercelllines; CVCL_0559
DR   CCRID; 1101HUM-PUMC000118
DR   CCRID; 1102HUM-NIFDC00101
DR   CCTCC; GDC0196
DR   Cell_Model_Passport; SIDM01470
DR   ChEMBL-Cells; CHEMBL3307972
DR   ChEMBL-Targets; CHEMBL612552
DR   CLS; 300434
DR   Cosmic; 787479
DR   Cosmic; 919129
DR   Cosmic; 924041
DR   Cosmic; 975302
DR   Cosmic; 1012123
DR   Cosmic; 1127259
DR   Cosmic; 1281355
DR   Cosmic; 2089658
DR   Cosmic; 2306240
DR   DepMap; ACH-000387
DR   DSMZ; ACC-334
DR   DSMZCellDive; ACC-334
DR   ECACC; 93022307
DR   GDSC; 1331044
DR   GEO; GSM743414
DR   GEO; GSM887704
DR   GEO; GSM888797
DR   GEO; GSM1374961
DR   IARC_TP53; 2197
DR   ICLC; HTL05001
DR   LiGeA; CCLE_592
DR   LINCS_LDP; LCL-1077
DR   Lonza; 1015
DR   NCBI_Iran; C602
DR   PharmacoDB; TF1_1588_2019
DR   Progenetix; CVCL_0559
DR   PubChem_Cell_line; CVCL_0559
DR   Wikidata; Q54972197
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1571549;
RX   PubMed=2656885;
RX   PubMed=2663885;
RX   PubMed=9096695;
RX   PubMed=9510473;
RX   PubMed=11021758;
RX   PubMed=11414198;
RX   PubMed=16408098;
RX   PubMed=22460905;
RX   PubMed=23955599;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=TF-1
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Characteristics: Proliferatively responsive to many growth factors.
CC   Characteristics: IL3 or CSF2 dependent.
CC   Doubling time: 39 +- 6 hours (PubMed=9096695); 22 hours (ATCC=CRL-2003); ~70 hours (DSMZ=ACC-334).
CC   HLA typing: A*02:01,33:03; B*08:20,51:01; C*01:02,14:03 (PubMed=26589293).
CC   HLA typing: A*02:01:01,33:03:01; B*44:03:01;51:01:01; C*01:02:01;14:03; DPA1*01:03:01,02:02:02; DPB1*04:01:01,02:01:02; DQA1*01:02:01,03:02; DQB1*06:09:01,06:09:01; DRA*01:01:01,01:02:02; DRB1*09:01:02,13:02:01 (DSMZCellDive=ACC-334).
CC   Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (PubMed=31160637).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); ClinVar=VCV001759367; Zygosity=Unspecified (PubMed=1571549).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.64%; Native American=0.04%; East Asian, North=79.7%; East Asian, South=18.49%; South Asian=0%; European, North=0%; European, South=1.13% (PubMed=30894373).
CC   Discontinued: BCRJ; 0233; probable.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): ATCC; CCRID; CLS; DSMZ; ECACC; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 13 (CCRID; CLS; DSMZ; ECACC)
ST   CSF1PO: 13,14 (ATCC; PubMed=25877200)
ST   D13S317: 8,9
ST   D16S539: 9,12
ST   D18S51: 13
ST   D19S433: 14,16
ST   D21S11: 30
ST   D2S1338: 19
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 12
ST   D8S1179: 11,15
ST   FGA: 18,19
ST   Penta D: 10,13 (CCRID; CLS; PubMed=25877200)
ST   Penta D: 13 (DSMZ)
ST   Penta E: 5,17
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C7152; Erythroleukemia
DI   ORDO; Orphanet_318; Acute erythroid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1571549; DOI=10.1182/blood.V79.9.2378.2378;
RA   Sugimoto K., Toyoshima H., Sakai R., Miyagawa K., Hagiwara K.,
RA   Ishikawa F., Takaku F., Yazaki Y., Hirai H.;
RT   "Frequent mutations in the p53 gene in human myeloid leukemia cell
RT   lines.";
RL   Blood 79:2378-2383(1992).
//
RX   PubMed=2656885; DOI=10.1002/stem.5530070202;
RA   Ihle J.N., Askew D.;
RT   "Origins and properties of hematopoietic growth factor-dependent cell
RT   lines.";
RL   Int. J. Cell Cloning 7:68-91(1989).
//
RX   PubMed=2663885; DOI=10.1002/jcp.1041400219;
RA   Kitamura T., Tange T., Terasawa T., Chiba S., Kuwaki T., Miyagawa K.,
RA   Piao Y.-F., Miyazono K., Urabe A., Takaku F.;
RT   "Establishment and characterization of a unique human cell line that
RT   proliferates dependently on GM-CSF, IL-3, or erythropoietin.";
RL   J. Cell. Physiol. 140:323-334(1989).
//
RX   PubMed=9096695; DOI=10.1038/sj.leu.2400621;
RA   Drexler H.G., Zaborski M., Quentmeier H.;
RT   "Thrombopoietin supports the continuous growth of cytokine-dependent
RT   human leukemia cell lines.";
RL   Leukemia 11:541-551(1997).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//